BioMarin Pharmaceutical(BMRN)
$56.70-1.63 (-2.79%)
BMRN
BioMarin Pharmaceutical stock forecast
$56.70
At close:-1.63 (-2.79%)
Want to see BMRN full AI Analyst Report?
BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target
2,472 Followers
BMRN Analyst Ratings
Moderate Buy
17Buy6Hold0Sell
Based on 23 analysts giving stock ratings to BioMarin Pharmaceutical in the past 3 months
BMRN Stock 12 Month Forecast
Average Price Target
$88.73â–˛(56.49% Upside)Based on 23 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $88.73 with a high forecast of $120.00 and a low forecast of $60.00. The average price target represents a 56.49% change from the last price of $56.70.
Past 12 Months12 Month ForecastJan2026Oct2026
High$120.00
Average$88.73
Low$60.00
Highest Price TargetHighest$120.00Average Price Target$88.73Lowest Price TargetLowest$60.00
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Sean Laaman | Morgan Stanley | $119→$103 | buy | 81.66%Upside | Assigned | 11/13/26 | ||
| Cory Kasimov | Evercore ISI | $120 | buy | 111.64%Upside | Reiterated | 11/13/26 | ||
| Mitchell Kapoor | H.C. Wainwright | $60 | hold | 5.82%Upside | Reiterated | 11/04/26 | ||
| Eliana Merle | Barclays | $114 | buy | 101.06%Upside | Reiterated | 11/04/26 | ||
| Jessica Fye | J.P. Morgan | $87→$86 | buy | 51.68%Upside | Reiterated | 11/04/26 | ||
| Mohit Bansal | Wells Fargo | $80 | buy | 41.09%Upside | Assigned | 11/03/26 | ||
| Paul Matteis | Stifel Nicolaus | $70→$66 | hold | 16.40%Upside | Reiterated | 11/03/26 | ||
| Yun Zhong | Wedbush | $94→$89 | buy | 56.97%Upside | Assigned | 11/03/26 | ||
| Joon Lee | UBS | $88 | buy | 55.20%Upside | Reiterated | 11/03/26 | ||
| Leland Gershell | Oppenheimer | $97→$94 | buy | 65.78%Upside | Reiterated | 11/03/26 | ||
| Phil Nadeau | TD Cowen | $120 | buy | 111.64%Upside | Reiterated | 11/03/26 | ||
| Eric Joseph | Citi | $76 | buy | 34.04%Upside | Reiterated | 11/02/26 | ||
| Luca Issi | RBC Capital | $62→$60 | hold | 5.82%Upside | Reiterated | 11/02/26 | ||
| Olivia Brayer | Cantor Fitzgerald | $86 | buy | 51.68%Upside | Reiterated | 11/02/26 | ||
| Jason Gerberry | Bank of America Securities | $86→$83 | buy | 46.38%Upside | Reiterated | 11/02/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Sean LaamanMorgan Stanley | BuyAssigned$119→$103 | 11/13/26 | 81.66%Upside | ||
| Cory KasimovEvercore ISI | BuyReiterated$120 | 11/13/26 | 111.64%Upside | ||
| Mitchell KapoorH.C. Wainwright | HoldReiterated$60 | 11/04/26 | 5.82%Upside | ||
| Eliana MerleBarclays | BuyReiterated$114 | 11/04/26 | 101.06%Upside | ||
| Jessica FyeJ.P. Morgan | BuyReiterated$87→$86 | 11/04/26 | 51.68%Upside | ||
| Mohit BansalWells Fargo | BuyAssigned$80 | 11/03/26 | 41.09%Upside | ||
| Paul MatteisStifel Nicolaus | HoldReiterated$70→$66 | 11/03/26 | 16.40%Upside | ||
| Yun ZhongWedbush | BuyAssigned$94→$89 | 11/03/26 | 56.97%Upside | ||
| Joon LeeUBS | BuyReiterated$88 | 11/03/26 | 55.20%Upside | ||
| Leland GershellOppenheimer | BuyReiterated$97→$94 | 11/03/26 | 65.78%Upside | ||
| Phil NadeauTD Cowen | BuyReiterated$120 | 11/03/26 | 111.64%Upside | ||
| Eric JosephCiti | BuyReiterated$76 | 11/02/26 | 34.04%Upside | ||
| Luca IssiRBC Capital | HoldReiterated$62→$60 | 11/02/26 | 5.82%Upside | ||
| Olivia BrayerCantor Fitzgerald | BuyReiterated$86 | 11/02/26 | 51.68%Upside | ||
| Jason GerberryBank of America Securities | BuyReiterated$86→$83 | 11/02/26 | 46.38%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering BioMarin Pharmaceutical
3 Months
Success Rate15/36 ratings generated profit
42%
Average Return
-0.44%
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.44% per trade.
1 Year
Success Rate19/42 ratings generated profit
45%
Average Return
-4.51%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 45.24% of your transactions generating a profit, with an average return of -4.51% per trade.
2 Years
Success Rate18/42 ratings generated profit
43%
Average Return
-2.23%
Copying Cory Kasimov's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -2.23% per trade.
BMRN Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 25 | 16 | 17 | 26 | 23 |
| Buy | 7 | 10 | 17 | 17 | 12 |
| Hold | 13 | 14 | 15 | 13 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 45 | 40 | 49 | 56 | 42 |
In the current month, BMRN has received 35 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 88.73.
BMRN Financial Forecast
High$0.96
Consensus$0.82
Low$0.66
BMRN Earnings Forecast
Next quarter’s earnings estimate for BMRN is $0.82 with a range of $0.66 to $0.96. The previous quarter’s EPS was $0.23. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$1.12B
Consensus$1.09B
Low$1.06B
BMRN Sales Forecast
Next quarter’s sales forecast for BMRN is $1.09B with a range of $1.06B to $1.12B. The previous quarter’s sales results were $1.02B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
BMRN Stock Forecast FAQ
What is BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is $88.73.
What is BMRN’s upside potential, based on the analysts’ average price target?
BioMarin Pharmaceutical has 56.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BMRN a Buy, Sell or Hold?
BioMarin Pharmaceutical has a consensus rating of Moderate Buy which is based on 17 buy ratings, 6 hold ratings and 0 sell ratings.
What is BioMarin Pharmaceutical’s price target?
The average price target for BioMarin Pharmaceutical is $88.73. This is based on 23 12-month price targets, issued in the past 3 months. The highest analyst price target is $120.00, the lowest forecast is $60.00. The average price target represents a 56.49% increase from the current price of $56.7.
What do analysts say about BioMarin Pharmaceutical?
BioMarin Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Street analysts.
How can I buy shares of BMRN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
